Subcutaneous Foslevodopa Infusion Cuts OFF-Related Nonmotor Fluctuations in Real-World Parkinson's Cohort

This single-center, uncontrolled cohort adds the first dedicated nonmotor fluctuation data for continuous subcutaneous foslevodopa/foscarbidopa infusion (CSFLI) and highlights discontinuation and neuropsychiatric considerations relevant to pharmacist-led patient selection and follow-up.

📅 Journal publication: Oct 2026 · Last updated: Oct 29, 2026

foslevodopafoscarbidopacontinuous subcutaneous infusionlevodopaParkinson's diseasenonmotor fluctuationsnonmotor symptomsdevice-aided therapyreal-world prospective cohortneurology Neurology / Neuropharmacology

Background Information

CSFLI reduces nonmotor fluctuations in Parkinson's patients.

Nonmotor fluctuations (NMFs) are challenging in Parkinson's disease, impacting quality of life significantly. Continuous subcutaneous foslevodopa/foscarbidopa infusion (CSFLI) reduced motor complications and NMFs, especially OFF-related symptoms, over three months. Limited to a single-center study, but offers promising real-world data on CSFLI's impact on nonmotor symptoms in Parkinson's disease. CSFLI shows potential in reducing nonmotor fluctuations and improving quality of life in Parkinson's disease.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.

Subscribe for $8/month → Read this one free →

Free account, no credit card. Includes 1 full deep analysis every month.

Authors: De Micco R, Ciaramaglia O, Siciliano M, Sant'Elia V, Cabato C, Ambrosio F, Tessitore A

Citation: De Micco R, Ciaramaglia O, Siciliano M, et al. Continuous Subcutaneous Foslevodopa/Foscarbidopa Improves Nonmotor Symptoms and Fluctuations in Parkinson's Disease. European journal of neurology. 2026;33(10). doi:10.1111/ene.70788

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Founding member rate

$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →

Free account, no credit card. Includes 1 full deep analysis every month.

Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.